Revenue: As of FY2026 Q1, the actual value is USD 102.25 M.

EPS: As of FY2026 Q1, the actual value is USD -2.16.

EBIT: As of FY2026 Q1, the actual value is USD -56.75 M.

Financial Metrics for GeneDx Holdings Corp.

Year Ended December 31, 2025

GAAP Measure Total Revenue: $427,539 thousand, with diagnostic test revenue at $416,668 thousand and other revenue at $10,871 thousand. Cost of Services: $129,366 thousand. Gross Profit: $298,173 thousand. Gross Margin: 69.7%. Operating Costs: Research and development was $72,026 thousand, and selling, general and administrative was $239,224 thousand. Loss from Operations: -$13,077 thousand. Interest Expense, Net: -$2,539 thousand. Other Expense, Net: -$5,521 thousand. Income Tax Benefit: $116 thousand. Net Loss: -$21,021 thousand.

Adjusted Measure Total Revenue: $427,539 thousand, comprising $416,668 thousand from diagnostic test revenue and $10,871 thousand from other revenue. Cost of Services: $123,201 thousand. Gross Profit: $304,338 thousand. Gross Margin: 71.2%. Operating Costs: Research and development was $65,496 thousand, and selling, general and administrative was $192,154 thousand. Income from Operations: $46,688 thousand. Other Income, Net: $512 thousand. Net Income: $47,200 thousand. Non-GAAP Adjustment for Non-Core Lease Costs: -$5,391 thousand.

Three Months Ended March 31, 2025

GAAP Measure Total Revenue: $87,115 thousand, with diagnostic test revenue at $85,759 thousand and other revenue at $1,356 thousand. Cost of Services: $28,639 thousand. Gross Profit: $58,476 thousand. Gross Margin: 67.1%. Operating Costs: Research and development was $12,577 thousand, and selling, general and administrative was $50,450 thousand. Loss from Operations: -$4,551 thousand. Interest Expense, Net: -$640 thousand. Other Income, Net: -$891 thousand. Income Tax Expense: -$447 thousand. Net Loss: -$6,529 thousand.

Adjusted Measure Total Revenue: $87,115 thousand, with diagnostic test revenue at $85,759 thousand and other revenue at $1,356 thousand. Cost of Services: $27,396 thousand. Gross Profit: $59,719 thousand. Gross Margin: 68.6%. Operating Costs: Research and development was $11,758 thousand, and selling, general and administrative was $39,028 thousand. Income from Operations: $8,933 thousand. Other Income, Net: $239 thousand. Net Income: $9,172 thousand. Non-GAAP Adjustment for Non-Core Lease Costs: -$1,481 thousand.

Three Months Ended June 30, 2025

GAAP Measure Total Revenue: $102,692 thousand, consisting of $100,100 thousand from diagnostic test revenue and $2,592 thousand from other revenue. Cost of Services: $31,790 thousand. Gross Profit: $70,902 thousand. Gross Margin: 69.0%. Operating Costs: Research and development was $15,079 thousand, and selling, general and administrative was $46,863 thousand. Income from Operations: $8,960 thousand. Interest Expense, Net: -$817 thousand. Other Income, Net: $2,420 thousand. Income Tax Benefit: $246 thousand. Net Income: $10,809 thousand.

Adjusted Measure Total Revenue: $102,692 thousand, with $100,100 thousand from diagnostic test revenue and $2,592 thousand from other revenue. Cost of Services: $30,208 thousand. Gross Profit: $72,484 thousand. Gross Margin: 70.6%. Operating Costs: Research and development was $13,448 thousand, and selling, general and administrative was $42,936 thousand. Income from Operations: $16,100 thousand. Other Income, Net: $288 thousand. Net Income: $16,388 thousand. Non-GAAP Adjustment for Non-Core Lease Costs: -$1,405 thousand.

Three Months Ended September 30, 2025

GAAP Measure Total Revenue: $116,743 thousand, including $113,523 thousand from diagnostic test revenue and $3,220 thousand from other revenue. Cost of Services: $32,216 thousand. Gross Profit: $84,527 thousand. Gross Margin: 72.4%. Operating Costs: Research and development was $19,829 thousand, and selling, general and administrative was $67,949 thousand. Loss from Operations: -$3,251 thousand. Interest Expense, Net: -$562 thousand. Other Expense, Net: -$3,575 thousand. Income Tax Expense: -$247 thousand. Net Loss: -$7,635 thousand.

Adjusted Measure Total Revenue: $116,743 thousand, with $113,523 thousand from diagnostic test revenue and $3,220 thousand from other revenue. Cost of Services: $30,623 thousand. Gross Profit: $86,120 thousand. Gross Margin: 73.8%. Operating Costs: Research and development was $18,034 thousand, and selling, general and administrative was $51,852 thousand. Income from Operations: $16,234 thousand. Other Expense, Net: -$176 thousand. Net Income: $16,058 thousand. Non-GAAP Adjustment for Non-Core Lease Costs: -$1,323 thousand.

Three Months Ended December 31, 2025

GAAP Measure Total Revenue: $120,989 thousand, including $117,286 thousand from diagnostic test revenue and $3,703 thousand from other revenue. Cost of Services: $36,721 thousand. Gross Profit: $84,268 thousand. Gross Margin: 69.6%. Operating Costs: Research and development was $24,541 thousand, and selling, general and administrative was $73,962 thousand. Loss from Operations: -$14,235 thousand. Interest Expense, Net: -$520 thousand. Other (Expense) Income, Net: -$3,475 thousand. Income Tax Benefit: $564 thousand. Net Loss: -$17,666 thousand.

Adjusted Measure Total Revenue: $120,989 thousand, with $117,286 thousand from diagnostic test revenue and $3,703 thousand from other revenue. Cost of Services: $34,974 thousand. Gross Profit: $86,015 thousand. Gross Margin: 71.1%. Operating Costs: Research and development was $22,256 thousand, and selling, general and administrative was $58,338 thousand. Income from Operations: $5,421 thousand. Other (Expense) Income, Net: $161 thousand. Net Income: $5,582 thousand. Non-GAAP Adjustment for Non-Core Lease Costs: -$1,182 thousand.

Q1 2026 Financial Highlights

Segment Revenue Total Revenue: $102.3 million for Q1 2026, a 17.4% increase from Q1 2025’s $87.115 million. GeneDx segment revenue: $101,496 thousand for Q1 2026, compared to $87,115 thousand for Q1 2025. Other segment revenue: $758 thousand for Q1 2026. Exome and genome revenue: Increased by 27% year-over-year to $90.6 million in Q1 2026, up from $71.4 million in Q1 2025 and $44.0 million in Q1 2024. Other revenue streams for Q1 2026: Included hereditary cancer revenue of $0.1 million, other panels revenue of $10.6 million, data information revenue of $0.8 million, and software and interpretation services revenue of $0.2 million.

Operational Metrics Exome and Genome Volume: Grew 34% year-over-year in Q1 2026 to 27,488 tests, compared to 20,562 tests in Q1 2025 and 16,592 tests in Q1 2024. Exome and Genome Portfolio Mix: Genomes represented 45% of the combined exome and genome portfolio in Q1 2026. Average Revenue Per Report (ARR): Approximately $3,300 in Q1 2026, with blended ARR lower due to a higher genome mix and lower parental samples mix. Adjusted Gross Margin: 69% for Q1 2026, with GeneDx contributing 68.9% and Other segments contributing 68.5%. Total Adjusted Gross Margin: 68.6% for Q1 2026, remaining flat year-over-year compared to 68.6% for Q1 2025. Adjusted Gross Profit: $70,053 thousand in Q1 2026, compared to $59,719 thousand in Q1 2025. Gross Margin (GAAP): 66.7% for Q1 2026, down from 67.1% for Q1 2025. Gross Profit (GAAP): $68,211 thousand for Q1 2026, up from $58,476 thousand for Q1 2025. Adjusted Total Operating Expenses: $78.1 million, representing 76% of revenue. Total GAAP Operating Expenses: $94.4 million. GAAP Loss from Operations: -$57,471 thousand for Q1 2026, compared to -$4,551 thousand in Q1 2025. Adjusted Loss from Operations: -$8,024 thousand for Q1 2026, compared to adjusted income from operations of $8,933 thousand in Q1 2025. Adjusted Net Loss: -$8.2 million for Q1 2026, compared to an adjusted net income of $9.172 million for Q1 2025. Net Loss (GAAP): -$63,316 thousand for Q1 2026, compared to a net loss of -$6,529 thousand for Q1 2025.

Cash Flow Cash Position: Cash, cash equivalents, marketable securities, and restricted cash totaled $171.7 million as of March 31, 2026. Net cash used in operating activities: -$32,408 thousand for Q1 2026, compared to net cash provided by operating activities of $10,182 thousand in Q1 2025. Net cash used in investing activities: -$17,255 thousand for Q1 2026, compared to -$9,408 thousand in Q1 2025.

2026 Guidance Update

GeneDx Holdings Corp. updated its full-year 2026 revenue guidance to between $475 to $490 million, a decrease from the previous guidance of $540 to $555 million. The company expects at least 30% growth in exome and genome volume, down from the prior 33% to 35% range, and anticipates an adjusted gross margin of approximately 70% with positive adjusted net income for the full year. For the second quarter of 2026, the company projects revenue of $110 to $112 million, approximately 30,000 exome and genome tests, an adjusted gross margin of approximately 70%, and an adjusted net loss of approximately -$5 million.

Other Key Information

Beginning with the quarter ended March 31, 2026, GeneDx Holdings Corp. reclassified “selling and marketing” and “general and administrative” into a single line item, “selling, general and administrative.” Additionally, the methodology for adjusted net income (loss) now includes an adjustment for non-core lease costs related to vacant laboratory facilities and office space.